MetaCap

Apollomics (APLM) vs Gain Therapeutics (GANX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apollomics (APLM) has outperformed Gain Therapeutics (GANX) over the past year, gaining 7.4% versus a loss of 62.4%. Over five years, GANX leads with a -87.3% price change compared with -98.4% for APLM. Apollomics is the larger company by market cap ($45.3 million vs $44.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+7.43%GANX-62.43%
+102%+15%-73%
Nov 21, 20251 yearNov 20, 2026
APLM-98.43%GANX-87.27%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus GANX key metrics
MetricAPLMGANX
Share price$15.54$0.9994
Market cap$45.28M$44.50M
1-day change-6.92%-4.82%
YTD return-16.90%-68.96%
1-year return+7.43%-62.43%
5-year return-98.43%-87.27%
EPS (TTM)$-0.25$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-53.86M$-20.16M
52-week high$28.29$4.34
52-week low$12.58$0.94
Distance from 52-week high-45.09%-76.97%
Analyst consensus—strong_buy
Avg. price target upside—+620.43%
Average volume11.07K550.22K
Shares outstanding2.91M44.53M
Employees1420
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APLM has outperformed GANX by 69.9 percentage points over the past year.

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Gain Therapeutics

GANX stock →

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

APLM vs GANX FAQ

Which is bigger, Apollomics or Gain Therapeutics?

Apollomics (APLM) is larger, with a market capitalization of $45.28M compared with $44.50M for Gain Therapeutics (GANX).

Which stock has performed better over the past year, APLM or GANX?

APLM returned +7.43% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and Gain Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons